Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 Thorough QT/QTc Study in Healthy Adults
NCT04560816Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atn-224 in Wilson's disease (6 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Placebo-corrected Change From Baseline QTcF for ALXN1840 at 24 hours. Started Jul 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson's disease
Beyond the preview
Go deeper on NCT04560816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560816.